Inovio Pharmaceuticals, Inc.

Good afternoon and welcome to the InnoVO Pharmaceuticals conference call. All participants will be in a listen only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to Thomas Hong, Manager of Investor Relations. Please go ahead.

Good afternoon and thank you for joining the Inovio second quarter 2022 financial results conference call. Joining me today on today's call are Dr. Jackie Shea, President and CEO, Mr. Peter Keyes, Chief Financial Officer, Dr. Michael Sumner, Chief Medical Officer, Dr. Laurent Humot, Chief Scientific Officer, Dr. David Leibowitz, Senior Vice President of Clinical Development for Infectious Diseases, and Dr. Jeffrey Skolnick, Senior Vice President of Clinical Development for Immuno-Oncology and HPV Therapeutics. Today's call will review our corporate and financial information for the quarter ended June 30th, 2022, as well as provide an update on our efforts to develop our DNA medicines platform. Following prepared remarks, we will conduct a question and answer segment. During the call, we will be making forward-looking statements regarding future events and the future performance of the company. These events relate to our business plans to develop Inovio's DNA medicines platform, which include clinical and regulatory developments and timing of clinical data readouts, along with capital resources and strategic matters. All of these statements are based on the beliefs and expectations of management as of today. Actual events or results could differ materially. We refer you to the documents we file from time to time with the SEC, which under the heading Risk Factors, identify important factors that could cause actual results to differ materially from those expressed by the company verbally, as well as statements made within this afternoon's press release. This call is being webcast live, and a link can be found on our website, ir.inovio.com, and a replay will be made available shortly after this call is concluded. I will now turn the call over to Inovio's president and CEO, Dr. Jackie Shea.

Thank you, Thomas. Good afternoon, and thank you, everyone, for joining today's call. At Inovio, our goal is to bring DNA medicines to market to help address unmet medical conditions and improve the health of people around the globe. We are dedicated to achieving this goal by building a leading biotechnology company that with an innovative pipeline of DNA medicine candidates from early research through late-stage clinical development to commercialization. During the second quarter, we focused on reshaping our organizational structure to align with our product development goals. We announced cost-cutting measures, including a corporate reorganization that resulted in an 18% reduction in our full-time workforce and an 86% reduction in contractors. These initiatives are expected to reduce our operating expenses by approximately 30% over the next 18 months and extend our cash runway into the third quarter of 2024. In addition, we also strengthened our executive leadership team and R&D organization with the addition of Dr. Michael Sumner, Anovio's new chief medical officer. Mike has been a strong addition to Inovio, bringing proven experience, strategy, and leadership to bear as we develop cutting-edge product candidates across multiple therapeutic areas. I'm pleased that Mike is already delivering great value through his insights and experiences, having taken several clinical products through to commercialization. I'd like to turn the call over to Mike now to briefly introduce himself.